Denosumab biosimilar (Mabtech Pharma)

地舒单抗生物类似药（迈博太科药业）

Report date: 2026/04/01 11:11:10

Base Information

Drug NameDenosumab biosimilar (Mabtech Pharma)
Drug Alias NameCMAB-807CMAB807X
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporotic FracturesOsteoporosis, PostmenopausalOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesTaizhou Mabtech Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Mabtech Pharmaceutical Co LtdShanghai Biomabs Pharmaceuticals Co LtdShanghai Maitai Yabo Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsOsteoporotic FracturesOsteoporosis, PostmenopausalOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A